Testing additional drugs for IgA nephropathy in South Asian patients
Part of Blood & lymphatic, Heart & circulation, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial is testing if adding another approved drug to standard treatment can slow kidney function decline in people with IgA nephropathy. It aims to find better options for South Asian adults with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have a kidney biopsy that shows IgA nephropathy.
- Your kidney function (eGFR) must be 20 or higher.
- You must have significant protein in your urine (at least 1 gram per day).
- You must already be on a stable dose of certain blood pressure and kidney-protecting drugs for at least 12 weeks.
- Your blood pressure must be controlled (systolic under 140, diastolic under 90).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This study tests a new medicine called CM313 for people with IgA nephropathy, a kidney disease. The goal is to see if it can help reduce protein in the urine and protect kidney function.
This trial tests whether choosing treatment based on your personal kidney findings can improve outcomes in adults with IgA nephropathy (IgAN). It may help by matching therapy to the type and severity of kidney damage seen on biopsy.
This trial tests a new medication for IgA nephropathy, a kidney disease that causes inflammation and protein loss in urine. It aims to see if the drug can safely slow down kidney damage and protect kidney function.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.